Yazar "Kucukkolbasi S." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Development of a spectrofluorimetric method for determination of thiabendazole in tablets
    (2013) Kucukkolbasi S.; Kilic E.
    In this study a spectrofluorimetric method has been developed for determination of thiabendazole drug active compound in tablets. For this purpose; thiabendazole drug activecompound was measured fluorescence intensities at excitation (?ex) and emission (?em) wavelength in various solvents. Suitable solvent was determined for each compound from calibration graphs and tablets' excipients. Spectrofluorimetric method for the determination of thiabendazole in tablet was described under the optimum conditions. The wavelengths of excitation and emission were 370,0 nm and 428.8 nm respectively. The fluorescence intensity was linearly related to the drug concentration and the method was found to be highly accurate and precise, having a relative standard deviation of less than 0.8 %. This proposed method was applied to the determination of thiabendazole in tablet. The validity of the method was tested by the recovery studies of standard addition to pharmaceuticals and the result was found to be satisfactory. The results compared with official USP 24 HPLC method were in good agreement and statistical comparison by means of Student's t-test and the variance ratio F-test showed no significant difference between the two methods. The proposed method is simple and sufficiently precise for quality control purposes in routine analysis.
  • Küçük Resim Yok
    Öğe
    Evaluation of h?D-1 and h?D-2 levels in saliva of patients with oral mucosal diseases
    (University of the West Indies, 2013) Kucukkolbasi H.; Kucukkolbasi S.; Ayyildiz H.F.; Dursun R.; Kara H.
    Objective: This study aimed to determine a possible correlation between oral mucosal disease and salivary concentrations of the antimicrobial peptides human beta-defensin-1 (h?D-1) and human betadefensin- 2 (h?D-2). Method: The present work focussed on the establishment of a reversed phase-high performance liquid chromatography (RP-HPLC) procedure to quantify human beta-defensins (h?D-1 and h?D-2) in saliva samples of patients with oral diseases such as lichen planus (n = 10), Behçet (n = 10) and recurrent apthous stomatitis (n = 10). Results: Linear calibration range for h?D-1 and h?D-2 defensins was 1.67-200 ?g mL-1 and 3.13 - 100 ?g mL-1 with R2 values of 0.9998 and 0.996, correspondingly. The concentration of beta-defensins in saliva was determined by comparing the peak areas of eluted h?D-1 and h?D-2 with that of their standards. The variation of the amount of beta-defensins was evaluated by comparisons of the results obtained from the patients with oral mucosal diseases before and after treatments and the control subjects. The limit of detection (LOD) and limit of quantification (LOQ) were found to be 1.62 ?g mL-1 and 5.39 ?g mL-1 for h?D-1 and 0.94 ?g mL-1 and 3.13 ?g mL-1 for h?D-2, respectively. Conclusion: The salivary beta-defensin concentration was significantly higher in patients with oral mucosal diseases than in healthy volunteers; furthermore, in patients with oral mucosal diseases, the concentration was significantly higher before treatment than after treatment.